Appendix 4E and Annual Report to Shareholders

• Signed USD$1.3M (AUD$2M) binding commercial agreement with Provider Network Solutions (PNS) in the US
• Completed technical development and re-platforming of 3DICOM software suite
• Raised AUD$11M in capital through strategic investments and share placements
• Maintained key quality, regulatory, and intellectual property certifications

The Board of Singular Health Group Limited is pleased to present a review of operations for the financial year ended 30 June 2025 ('FY2025'). During the year, the Group focused on advancing a strategic collaboration with Provider Network Solutions (PNS) in the United States, culminating in a USD$1.3M (approximately AUD$2M) binding commercial agreement. The Group also expedited the technical development and re-platforming of the 3DICOM software suite, building corporate relationships, enhancing investor engagement, and consolidating the Group's financial position. Key achievements included strengthening quality systems, regulatory compliance, and intellectual property protection, as well as divesting non-core business units to focus on software development and commercialisation. The Group raised AUD$3 million in November 2024 and a further AUD$8 million in June 2025, which sets it up for the planned US national rollout of 3DICOM, further product development, and working capital requirements. The year ahead will focus on delivering measurable results from the PNS commercial contract, expanding nationally in the US via the PNS network and other partners, driving adoption in healthcare and education sectors, and continuing to build shareholder value through innovation, compliance, and disciplined execution.

The Group signed a USD$1.3M (approximately AUD$2M) binding commercial agreement with Provider Network Solutions (PNS) for the pilot implementation of the Group's 3DICOM solution and staged deployment of 1,000 3DICOM MD licences across the PNS network.

With a strong capital base, advanced technology platform, and an expanding network of strategic partnerships, the Group is well positioned to accelerate the commercialisation of the 3DICOM solution in the United States and other key markets. The year ahead will focus on delivering measurable results from the PNS commercial contract, expanding nationally in the US via the PNS network and other partners, driving adoption in healthcare and education sectors, and continuing to build shareholder value through innovation, compliance, and disciplined execution.